Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Diuretic Resistance in Heart Failure
NCT05323487Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bumetanide in heart failure (HF) (4 arms), sponsored by Yale University. Primary endpoints: Change in fractional excretion of lithium, Change in distal sodium reabsorption and 2 more. Started Jun 2022; status: recruiting.
02
Drugs
bumetanide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05323487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323487.